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Abstract. The relative protective efficacy of oral administration of mycobacteria as 
compared to the conventional intradermal route of vaccination has been assessed in 
guinea pigs. Skin test reactivity to partially purified protein derivative and protective 
immunity to challenge with virulent Mycobacterium tuberculosis were used as parameters 
of protective immunity. 
Oral immunisation of guinea pigs either with BCG or with Mycobacterium avium 
intracellulare induces skin test reactivity and protective immunity comparable to that 
induced by intradermal route of vaccination. Oral exposure of Mycobacterium avium 
intracellulare prior to oral or intradermal dose of BCG did not interfere with the protective 
immunity induced by BCG in guinea pigs challenged with Mycobacterium tuberculosis 
H37Rv. 
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Introduction 
 
The immune response is modulated by the nature, quantity and duration of the 
immunogen challenge. The oral route is one path by which the immune system 
comes into contact with an invading organism or its antigens. With recent advances 
in the immunological concepts there is a growing interest in the effects of oral 
exposure to antigens (Kagnoff, 1978). 
It has long been held that oral intake of mycobacterial antigen can be a means of 
conferring protective immunity against tuberculosis. Indeed as early as in 1957 the 
oral administration of BCG to man was shown to confer delayed type hypersensi 
tivity (DTH) (De Assis, 1957). The justification for oral BCG administration was 
the fact that infection by tubercle bacilli commonly took place by ingestion. Also, it 
was known that the incompletely differentiated intestinal mucous membrane, 
present immediately after birth, was permeable to microbial transit towards the 
lymphatic and blood circulation. Further, autopsy studies proved that BCG passed 
through the intestinal membrane (Sol Roy Rosenthal, 1980). However, the value of 
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oral BCG vaccination in protection against disease was never adequately 
established in animals or in man, having been superseded by intradermal 
vaccinaton which can yield high protection (leading article in Tubercle, 1960). 
Nevertheless, with the failure of intradermal BCG to confer more than a slight 
protection in some recent clinical trials there is renewed interest in oral BCG 
(Tuberculosis Prevention Trial, 1980). This interest arises from two different points 
of view: (i) either oral BCG might be superior to intradermal BCG in conferring 
protective immunity since it mimicks the natural route of infection and (ii) in some 
regions of the world, natural oral exposure to environmental mycobacteria might 
play the role of natural vaccination or even deviate the immune responses thus 
preventing the protective effect of BCG vaccination. 
The latter possibility that prior infection with various non tuberculous 
mycobateria (NTM) might in some way cross protect against subsequent infection 
by Mycobacterium tuberculosis was examined by Youmans et al. (1961). Palmer 
and Long (1966) tested this hypothesis and found that infection with NTM could 
provide as much as 50% protective effect as that produced by BCG. 
Rook et al. (1981) postulated that two types of cell mediated responses could 
result in persons exposed to certain NTM prior to BCG vaccination; 'the Koch 
type' and the 'Listeria type' reactions. The former results in blocking the 
generation of acquired immunity to BCG vaccine whereas the latter enhances the 
protection. Orme and Collins (1983), using M. kansasii in mice found no 
interference by M. kansasii on BCG vaccination. But they speculated that oral 
immunisation (exposure) with M. avium intracellulare (MAI) complex might 
induce tolerance which might interfere with the immune response to subsequent 
BCG immunisation. 
Among all the atypical mycobacteria isolated and identified so far from the BCG 
trial area in South India, MAI is the most common (Paramasivan et al., 1985). 
Hence, in our present study, we have examined whether oral exposure to MAI 
influences the protective immunity offered by BCG. 
 
 
Materials and methods  
 
Animals 
 
Random bred male guinea pigs maintained at the Tuberculosis Research Centre 
and weighing 300-400 g were used. 
 
Experimental design 
The experimental schedule is outlined in table 1. 
 
BCG administration 
 
Freeze-dried BCG vaccine, (Central BCG Laboratory, Guindy, Madras) was used 
for both intradermal and oral vaccination. Two mg of BCG is equivalent to 
2.0 × 107 colony forming units. 
For intradermal vaccination a dose of 0.075 mg BCG in 0.1 ml was injected 
intradermally in the shaved right flank. BCG was orally administered with a 
specially devised L-shaped canula attached to a syringe. 
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Table 1. Experimental design. 
 
 
Skin test reactivity to partially purified protein derivative 
Ten µg of partially purified protein derivative (PPD) (Weybridge Laboratories, 
England) in 0·1 ml was injected intradermally on the left flank 3 days 
before challenge infection. The skin test reaction was assessed after 24, 48 and 72 h 
and the diameter of the area of induration measured in millimetres. 
 
MAI 
One of the MAI strains isolated from the BCG trial area in South India during 1981 
was used. 
 
M. tuberculosis strain H37Rv 
The H37Rv strain used was the strain maintained in Tuberculosis Research Centre, 
Madras. It has been periodically passaged in guinea pigs and is subcultured on 
Lowenstein Jensen medium (LJ medium). 
 
Assessment of protection after vaccination 
 
Challenge with M. tuberculosis H37Rv: All groups of animals were challenged with 
virulent tubercle bacilli 3 weeks after vaccination, by injecting subcutaneously 1 mg 
moist weight of the bacilli in 0.5 ml of distilled water in the right thigh of each 
animal. 
 
Assessment of tubercular lesion: All surviving animals were sacrificed after 42 days 
and the extent of disease present in the various organs scored after randomization 
of the animals. Any animal dying earlier was examined by autopsy and the extent of 
disease scored. The scoring system of Mitchison et al. (1960) was adopted. 
Morphological scores based on the severity of the disease (No. of tubercles, areas 
of necrosis and caseation) for the spleen were 0, 10, 20, 30 and 40; for the liver: 0, 
8, 15, 23 and 30; for the lungs: 0, 5, 10, 15 and 20; and, for the site of inoculation 
and its draining lymphnodes, values were from 0-10 depending on the extent of 
involvement of the regional glands. Thus, macroscopic scores ranged from a 
minimum of 0 to a maximum (of 100) score for all organs of severely diseased 
animals of 100. 
 
The mean root index: The mean root index (MRI) was obtained by dividing the 
total score by the number of days of survival of the animals (irrespective of whether 
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they died or were killed) and taking its square root. The root index of disease thus 
served as a measure of the degree of protection afforded by vaccination, the smaller 
the root index, the greater the protection. 
 
Colony counts on spleen homogenates: A portion of the spleen taken aseptically 
from the animal was weighed and homogenised in 5 ml distilled water. The number 
of colony forming units (cfu) was determined by inoculating LJ medium 
with serial dilutions of the homogenate. Colonies were counted 6 and 8 weeks after 
incubation. The viable count (VC) was calculated as follows: 
 
 
 
Results 
 
Table 2 shows the result of various doses of oral BCG administration on DTH and 
protection against challenge with M. tuberculosis H37Rv. The intradermally 
vaccinated animals developed skin test reactivity (mean induration of 12.7 mm) 
and showed a MRI of 0.78. The mean log viable count of bacilli in the spleen was 
4.3. None of the animals receiving oral doses ranging from 0·075-6 mg developed 
skin test reactivity or protective immunity. 
 
Table 2. Lack of effect of smaller doses of oral BCG immunisation on DTH and 
protection against challenge with H37Rv. 
 
 
a 6 animals per group. 
b 10 µg PPD was injected interadermally and reading were taken at 24.48 and 
72 h. 
C Mean of the square root of total score divided by No.of survival days. 
 
Since a single oral dose of 6 mg of BCG failed to sensitize or confer immunity the 
effect of a large single dose (30 mg) or 6 multiple doses (consecutive days) of 5 or 
10 mg were tested and the results are summarised in table 3. Both groups of 
animals developed skin test reactivity and protective immunity. 
Subsequently, the effect of oral immunisation with MAI was studied using a 
single dose of 30 mg. Table 4 shows that, the guinea pigs which were given either 
intradermal or oral BCG immunisation showed a positive skin test reaction and a 
lower MRI. Similar results were seen with animals exposed to oral MAI. 
The influence of MAI on BCG induced protective immunity when given orally 
prior to BCG is shown in table 5. The animals which were exposed to MAI prior to 
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Table 3. DTH responsiveness and protection against challenge with Μ. tuberculosis H37Rv after  
larger doses of oral BCG. 
a6 animals in each group. 
 
T a b l e  4 .  D T H  a n d  p ro t e c t iv e  i mmu n i t y  i ndu c ed  b y  M A I .  
a 5 animals each group 
 
 
BCG developed skin test reactivity (induration of 17.3 mm) and showed a MRI of 
0·52. 
Table 6 shows the influence of MAI on BCG induced protective immunity when 
given orally 3 weeks prior to intradermal BCG. The control animals gave a MRI of 
0·95 and a viability count of 17 × 103 In contrast, the group of animals which 
received BCG (orally alone) and the group which received MAI (orally) prior to 
intradermal BCG showed a lower MRI and lower viability count when compared to 
those of controls (P < 0·05). 
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Table 5. Influence of MAI on BCG induced protective 
immunity when given orally 3 weeks prior to oral BCG. 
 
a 3 animals in each group. 
Ρ values—Control versus BCG (oral) < 0·05; 
Control versus M. avium < 0·05; 
Control versus M. avium 
3 weeks prior to BCG < 0·05. 
 
Table 6. Influence of prior oral exposure of MAI on BCG induced protective 
immunity. 
a Consists of 5 animals in each group. 
b Ρ value is significant when MRI of oral BCG immunised animals and the animals 
which received oral MAI and intradermal BCG were compared with control 
group(< 0·05). 
c Ρ value is significant when viability count of oral BCG immunised animals and 
the animals which received oral MAI and intradermal BCG were compared with 
control group (< 0·05). 
When the MRI and the VC of oral BCG immunised animals were compared with 
hose of the animals which received oral MAI and subsequent intradermal BCG 
there was no significant difference. 
 
Discussion 
 
High prevalence of atypical mycobacterial infection with resultant sensitization in 
the population of the BCG study area in Chingleput District, has been implicated 
as one of the mechanisms for the lack of protection by BCG against adult type of 
tuberculosis. The present study was carried out to examine the hypothesis, that oral 
exposure to MAI influences the protective immunity offered by BCG. 
The initial experiments were set up to establish the protective immunity offered 
by oral BCG. Three weeks after oral immunisation with BCG, guinea pigs 
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developed marked skin test reactivity to PPD-S. A single oral dose of live BCG 
upto 6 mg weight did not induce skin test positivity whereas in separate 
experiments a dose of 30 mg was effective. 
As there is no immunological test, either in vivo or in vitro, that correlates fully 
 with protective immunity, an in vivo challenge with virulent M. tuberculosis H37 Rv 
 was chosen as the means to examine protective immunity. It was seen that doses of 
 BCG that did not confer delayed type hypersensitivity did not confer protection 
 and protection was always seen when DTH was present. Nevertheless, there was no 
correlation between extent of delayed type hypersensitivity and degree of immunity 
 as revealed by either lower viability count or lower disease indices. 
Oral immunisation with MAI resulted in a mean skin induration of 7.8 mm as 
compared to 10 mm and 9.2 mm in animals given BCG orally or intradermally. 
This difference in skin test induration to PPD-S bears no relationship to MRI 
because MAI infected animals gave the lowest MRI as compared to those in 
animals given oral or intradermal BCG. Similar observations were obtained in 
groups of animals primed with MAI prior to BCG administration. 
Rook et al (1981) proposed the hypothesis that contact with NTM might in some 
 way jeopardise or interfere with the generation of acquired cell mediated immunity 
resulting from BCG immunisation and hence provide an explanation for the failure 
 of the recent BCG trial in South India. Orme and Collins, (1983) concluded from 
 their experiment that despite the presence of M. kansasii infection BCG vaccinated 
animals were fully resistant to subsequent aerosol challenge with virulent M. 
 tuberculosis. Continuing in a similar line Orme and Collins (1984), using animals 
 with pulmonary infection by M. kansasii, M. Simiae, M. avium and M. 
 scrofulaceum showed that subsequent intravenous inoculation with 106 BCG had 
 no discernible effect on the course of NTM infection within the lungs. However, all 
 the BCG vaccinated group were fully resistant to subsequent acute aerogenic 
 challenge with M. tuberculosis regardless of the presence of pulmonary NTM 
 infection. Edwards et al. (1982) and more recently Smith et al (1985) reported that 
there was no interference due to MAI on the protective efficacy of BCG by using 
an aerosol challenge model in the guinea pigs. Collins (1983) nevertheless 
hypothesised that oral infection caused by MAI might induce immunological 
perturbation within the host capable of interfering with subsequent immune 
response. 
Results of the present study using guinea pigs as model system, showed that oral 
exposure with MAI did not interfere with the protective immunity induced by 
BCG. 
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